Develop, Validate & Implement Cell-Based & Biophysical Analytical Methods to Guarantee Safe, High Quality, Consistent & Efficacious Gene Therapy Products at Scale

The past twelve months have culminated in an unprecedented level of excitement, investment, and clinical progress within the gene therapy field. As the field strives to strike a delicate balance between safety and efficacy, in the context of increased regulatory scrutiny and safety challenges, attending the 4th Annual Gene Therapy Analytical Development as an analytical scientist has never been so important.

This year’s summit returns in-person to Boston to reunite 300+ analytical experts in innovative biotech, pharma and academia to continue to develop resilient, long-lasting and robust analytical tools to enhance the safety, quality and efficacy of gene therapy products.  

Whether you are focusing on specific characterization methods, enhancing your genome sequencing, advancing your understanding of full and partial particles, or advancing your early-stage bioassays, with 4 tracks, 8 pre-conference workshops and a post-conference focus day, the 4th Gene Therapy Analytical Development Summit will encompass all aspects of analytical development, giving you the chance to address and overcome challenges.

If you work in quality control, quality assurance, or process development - we’ve listened and we’ve answered. This year’s agenda includes a novel track designed for quality control and process development groups working in gene therapy. Talks include enhancing the knowledge transfer between departments, bridging between analytical methods with regards to QC/PD, and enhancing in-process development support.

Whether you're working with AAV, non-viral vectors or lentiviral vectors, this is your opportunity to enhance your existing analytical methods and explore innovative new tools to support safe and effective gene therapy development.

4 Dedicated New Tracks of Content in 2022:


Discover the latest updates in potency assay strategies, platform assay development & developing bioassays for downstream biological effects


Deep dive into enhancing knowledge transfer between AD, QC & PD teams & optimizing process development and manufacturing processes


Further your understanding of your full, empty, & partial particles by enhancing your characterization methods


Explore next-generation sequencing techniques, advancements in titre metrics & emerging characterization technologies

World-Class 2022 Speaking Faculty Included:

Connie Tsai

Associate Director, Analytical Development

Novartis Gene Therapies

Dwayne Neal

Senior Director, Analytical Sciences & Technology


Jarrod Dean

Associate Director, NGS Leader, Genomics Medicine Unit CMC


Susan Sleep

Director, Assay Development


Zoran Sosic

Associate Director of Gene Therapy Analytical Chemistry